- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03451084
A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
A Phase IIA Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia
Study Overview
Detailed Description
ASLAN003-003 is a multi-center, Phase IIA study to determine the optimum dose of ASLAN003 based on the safety, efficacy, and tolerability of varying doses of ASLAN003 (100 mg QD, 200 mg QD, 100 mg BID, and possibly 200 mg BID) administered to AML subjects daily for a continuous 28-day treatment cycle until disease relapse, disease progression, unacceptable toxicity, or withdrawal of consent.
The study has 2 parts and plans to enroll a total of 44 to 56 patients with 18 to 24 patients in Part 1 and 26 to 32 patients in Part 2 (comprising Parts 2A and 2B). The Overall Complete Remission Rate will be evaluated in AML patients not eligible for standard treatment (Part 1) and in relapsed and refractory AML patients (Part 2A) using the optimum dose of ASLAN003 established in Part 1 of the study. In Part 2B of the study, the appropriate dose of ASLAN003 in combination with azacitidine in older (more than or equal to 60 years) AML patients who have exhausted any approved and available treatment options will be determined.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
Albury, New South Wales, Australia
- 1 Site
-
Darlinghurst, New South Wales, Australia
- 3 Sites
-
Waratah, New South Wales, Australia
- 1 Site
-
-
Queensland
-
Douglas, Queensland, Australia
- 1 Site
-
-
South Australia
-
Adelaide, South Australia, Australia
- 1 Site
-
-
Victoria
-
Melbourne, Victoria, Australia
- 3 Sites
-
-
-
-
-
Singapore, Singapore
- 3 Sites
-
-
-
-
Kentucky
-
Louisville, Kentucky, United States, 40241
- 1 Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who are of or older than 18 years old in the United States or are of or older than the legal age in the respective countries at the time when written informed consent is obtained
- Patients who are able to understand and willing to sign the informed consent form (ICF)
- Patients who are diagnosed with AML according to the 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia (refer to Appendix 1: WHO Classification of Acute Myeloid Leukemia)
- Patients who have a sufficient archival or fresh BM aspiration sample for the evaluation of relevant exploratory endpoint.
Note: Patients who do not have sufficient archival BM aspiration sample and refuse to repeat the procedure may be enrolled in the trial only after written confirmation by ASLAN 5. Part 1: Patients who are ineligible for standard treatment of AML including to the following conditions:
- Patients who are ineligible for chemotherapy, and have exhausted any approved and available treatment options. More details on patients who are considered as ineligible or unfit for chemotherapy as per Ferrara et al, Leukemia, 2013 can be found in Appendix 4.
- Patients who have relapsed from prior remission;
Patients who have failed to respond to prior therapy including chemotherapy, hypomethylating agents, and bone marrow transplantation.
5. Part 2A: Patients who have relapsed or refractory AML to treatments including chemotherapy, hypomethylating agents, bone marrow transplantation, and other anti-leukemic agents
- Relapsed patients who have bone marrow blasts ≥5%; or reappearance of blasts in the blood; or development of extramedullary disease after prior CR or CRi
Refractory patients who have no CR or CRi after 2 courses of intensive induction treatment 5. Part 2B: Older patients (more than or equal to 60 years) AML patients who have exhausted any approved and available treatment options.
6. Patients who have an ECOG performance status of ≤ 2 7. Patients with adequate renal and hepatic function, as defined below:
- Estimated Glomerular Filtration Rate (eGFR) or creatinine clearance (CrCl) (CrCl calculated by the Cockroft and Gault method) ≥ 40 ml/min/1.73 m2
- Total bilirubin, AST, and ALT ≤ 1.5 × ULN
Exclusion Criteria:
- Patients who are diagnosed with de novo myeloid sarcoma without BM involvement
- Patients who are diagnosed with acute promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA)
- Patients who received any other standard or investigational treatment for their leukemia within the last 7 days before starting the first dose of study drug, with the exception of leukapheresis and hydroxyurea
- Patients with unresolved serious toxicity (≥ CTCAE 4.03 Grade 2) from prior administration of standard or investigational treatment for their leukemia
- Patients who have a positive test for human immunodeficiency virus (HIV), viral hepatitis C infection (patients with sustained viral response are not excluded), active viral hepatitis B infection (positive hepatitis B surface antigen [HBsAg]) with hepatitis B virus deoxyribonucleic acid (DNA) exceeding 2000 IU/ml
- Patients who have a known history of liver cirrhosis Child-Pugh score B or C
- Patients who have any history of other malignancy unless in remission for more than 1 year (skin carcinoma and carcinoma-in-situ of uterine cervix treated with curative intent is not exclusionary)
- Female patients who are pregnant or breast-feeding
- Patients with a known history of alcohol or drug addiction on the basis that there could be a higher risk of non-compliance to study treatment
- Patients with a history or presence of a clinically significant condition which in the opinion of the Investigator could jeopardize the safety of the patient or the validity of the study results
- Patients who have been previously treated with ASLAN003
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Part 1: Dose Level 1
|
Patients will be administered with the study drug, ASLAN003.
The study drug is to be administered orally, QD or BID.
It is recommended to administer the study drug with food or within 30 minutes after food intake.
|
EXPERIMENTAL: Part 1: Dose Level 2
|
Patients will be administered with the study drug, ASLAN003.
The study drug is to be administered orally, QD or BID.
It is recommended to administer the study drug with food or within 30 minutes after food intake.
|
EXPERIMENTAL: Part 1: Dose Level 3
|
Patients will be administered with the study drug, ASLAN003.
The study drug is to be administered orally, QD or BID.
It is recommended to administer the study drug with food or within 30 minutes after food intake.
|
EXPERIMENTAL: Part 1: Dose Level 4
|
Patients will be administered with the study drug, ASLAN003.
The study drug is to be administered orally, QD or BID.
It is recommended to administer the study drug with food or within 30 minutes after food intake.
|
EXPERIMENTAL: Part 2:ASLAN003 at Optinum Dose Level -1 & Azacitidine
|
Patients will be administered with the study drug, ASLAN003.
The study drug is to be administered orally, QD or BID.
It is recommended to administer the study drug with food or within 30 minutes after food intake.
|
EXPERIMENTAL: Part 2:ASLAN003 at Optinum Dose Level & Azacitidine
|
Patients will be administered with the study drug, ASLAN003.
The study drug is to be administered orally, QD or BID.
It is recommended to administer the study drug with food or within 30 minutes after food intake.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Complete Remission Rate
Time Frame: 4 months after study treatment
|
Defined as the proportion of patients with a best response of complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), defined in accordance with the IWG Response Criteria in AML from day 29. Treatment failure is defined as not achieving any response 4 months after study treatment. IWG Response Criteria in AML defines CR or CRi as:
|
4 months after study treatment
|
Number of Participants With Adverse Events
Time Frame: Through 28 days post last study medication administration
|
Number of Participants with Adverse Events reported through 28 days post last study medication administration
|
Through 28 days post last study medication administration
|
Safety Assessments
Time Frame: Through 28 days post last study medication administration
|
Safety Assessments - Clinical laboratory test: Hematology and Chemistry
|
Through 28 days post last study medication administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse Free Survival
Time Frame: From 12 weeks post end of treatment (EOT) until the date of first documented relapse or date of death from any cause, whichever came first, assessed up to 24 months
|
Defined as the time the criteria for remission (CR or CRi) are first met until there is evidence of patient relapse, regardless of whether the patient is still taking study drug. Relapse is defined as:
|
From 12 weeks post end of treatment (EOT) until the date of first documented relapse or date of death from any cause, whichever came first, assessed up to 24 months
|
Clinical Benefit Rate
Time Frame: 4 months after study treatment
|
Defined as the proportion of subjects with an AML IWG best response of CR, CRi or PR. IWG Response Criteria in AML defines CR, CRi or PR as:
|
4 months after study treatment
|
% Change From Baseline in BM Blasts at Day 29
Time Frame: Baseline and day 29
|
Percent Change from Baseline in BM Blasts at Day 29
|
Baseline and day 29
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASLAN003-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Uma BorateNot yet recruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 MutationUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
Clinical Trials on ASLAN003
-
ASLAN PharmaceuticalsCompletedHealthy VolunteersSingapore
-
ASLAN PharmaceuticalsRecruiting
-
ASLAN PharmaceuticalsCompletedHealthy Elderly Subjects (Age ≥55 Years)Singapore